tiprankstipranks
Trending News
More News >
Fonar Corp (FONR)
NASDAQ:FONR

Fonar (FONR) AI Stock Analysis

Compare
90 Followers

Top Page

FO

Fonar

(NASDAQ:FONR)

Rating:67Neutral
Price Target:
$14.50
▲( 5.84% Upside)
Fonar's overall stock score is driven by solid financial performance and reasonable valuation. However, technical analysis suggests potential caution due to bearish trends and overbought conditions. The lack of earnings call or corporate events information does not contribute to the score, keeping the focus on financial health and technical indicators.

Fonar (FONR) vs. SPDR S&P 500 ETF (SPY)

Fonar Business Overview & Revenue Model

Company DescriptionFonar Corporation, founded in 1978, is a pioneer in the medical imaging industry, particularly known for its development of magnetic resonance imaging (MRI) technology. The company operates primarily in the healthcare sector, focusing on the design, manufacture, and sale of MRI scanners. Fonar is notable for its Upright MRI, which allows patients to be scanned in a variety of positions, including sitting or standing, which can be crucial for diagnosing certain conditions that are affected by gravity.
How the Company Makes MoneyFonar makes money through the sale and leasing of its MRI equipment, particularly the Upright MRI scanners. The company also generates revenue by providing maintenance and servicing for MRI systems. Additionally, Fonar has a subsidiary, Health Management Corporation of America (HMCA), which manages diagnostic imaging centers. These centers not only use Fonar's MRI technology but also provide a source of recurring revenue through patient scans and related services. The company benefits from partnerships with healthcare providers and institutions that utilize its advanced imaging technology, thereby expanding its market reach and customer base.

Fonar Financial Statement Overview

Summary
Fonar's financial statements reflect a company with solid profitability and cash generation capabilities, albeit with potential leverage risks due to a high debt-to-equity ratio in the latest period. The company exhibits consistent revenue growth and effective cost management. However, ongoing attention to leverage and cash flow stability is recommended to sustain financial health.
Income Statement
75
Positive
The income statement shows a healthy profitability profile with a strong gross profit margin and consistent EBIT and EBITDA margins. The company has shown revenue growth over the past periods, although the growth rate has recently slowed down. The net profit margin remains solid, indicating efficient cost management.
Balance Sheet
65
Positive
The balance sheet demonstrates a relatively high debt-to-equity ratio due to zero equity reported in the latest TTM period, indicating potential financial leverage risks. However, previous annual data shows stable equity levels and a reasonable equity ratio. The return on equity is noteworthy when equity was present, reflecting effective use of shareholders' funds.
Cash Flow
70
Positive
Cash flow statements reveal strong free cash flow generation and a solid operating cash flow to net income ratio, indicating good cash conversion efficiency. Nonetheless, fluctuations in free cash flow growth suggest potential variability in cash generation capabilities.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
77.88M102.88M98.65M97.59M89.93M85.69M
Gross Profit
27.50M45.14M45.75M47.01M43.47M42.39M
EBIT
12.04M16.54M14.79M22.01M17.10M8.81M
EBITDA
18.20M28.25M24.61M31.65M23.45M19.14M
Net Income Common Stockholders
11.07M10.57M9.38M17.23M13.67M11.70M
Balance SheetCash, Cash Equivalents and Short-Term Investments
0.0056.48M51.31M48.76M44.49M36.83M
Total Assets
0.00214.25M200.58M199.34M189.51M180.26M
Total Debt
39.79M41.68M37.01M38.22M34.69M35.77M
Net Debt
39.79M-14.67M-14.27M-10.51M-9.77M-1.03M
Total Liabilities
40.62M57.46M49.75M53.11M54.14M54.02M
Stockholders Equity
0.00165.97M157.91M150.29M138.42M126.19M
Cash FlowFree Cash Flow
8.07M13.27M10.13M10.67M14.27M12.76M
Operating Cash Flow
11.64M14.09M14.47M15.30M19.09M20.40M
Investing Cash Flow
-3.51M-850.74K-4.34M-5.18M-4.82M7.42M
Financing Cash Flow
-7.86M-8.18M-7.57M-5.86M-6.61M-4.90M

Fonar Technical Analysis

Technical Analysis Sentiment
Positive
Last Price13.70
Price Trends
50DMA
12.96
Positive
100DMA
14.10
Negative
200DMA
15.11
Negative
Market Momentum
MACD
0.20
Negative
RSI
60.54
Neutral
STOCH
80.96
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FONR, the sentiment is Positive. The current price of 13.7 is above the 20-day moving average (MA) of 12.62, above the 50-day MA of 12.96, and below the 200-day MA of 15.11, indicating a neutral trend. The MACD of 0.20 indicates Negative momentum. The RSI at 60.54 is Neutral, neither overbought nor oversold. The STOCH value of 80.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FONR.

Fonar Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
$89.13M11.215.00%0.29%-22.13%
63
Neutral
$77.79M43.683.46%24.75%-61.29%
54
Neutral
$97.80M-26.20%20.81%-498.66%
53
Neutral
$5.24B3.07-43.58%2.80%16.87%-0.11%
46
Neutral
$48.44M-67.86%0.34%6.20%
46
Neutral
$57.98M-160.70%1.92%6.23%
39
Underperform
$53.23M-94.65%-5.86%50.76%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FONR
Fonar
13.70
-1.76
-11.38%
CTSO
Cytosorbents
0.87
-0.07
-7.45%
XTNT
Xtant Medical Holdings
0.69
-0.09
-11.54%
SRTS
Sensus Healthcare
4.71
-1.12
-19.21%
HYPR
Hyperfine
0.59
-0.32
-35.16%
ICCM
Icecure Medical
1.03
-0.03
-2.83%

Fonar Corporate Events

Executive/Board ChangesShareholder Meetings
Fonar Holds Annual Stockholders Meeting and Elections
Neutral
May 19, 2025

On May 19, 2025, Fonar Corporation held its Annual Meeting of Stockholders at the Hilton Long Island Huntington Hotel in Melville, New York. During the meeting, stockholders elected five directors, approved executive compensation, and ratified CohnReznick LLP as the auditors for the fiscal year ending June 30, 2025. The re-elected directors include Timothy R. Damadian, M.D., Claudette J. V. Chan, Ronald G. Lehman, Richard E Turk, and Jessica Maher.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.